International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
15
1
1
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
6.7%
1 terminated/withdrawn out of 15 trials
92.9%
+6.4% vs industry average
93%
14 trials in Phase 3/4
92%
12 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Role: collaborator
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Role: collaborator
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Role: collaborator
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Role: collaborator
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Role: collaborator
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Role: collaborator
ACTIV-3: Therapeutics for Inpatients With COVID-19
Role: collaborator
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
Role: collaborator
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Role: collaborator
Observational Study of C. Diff in Post-Transplant Patients
Role: collaborator
All 15 trials loaded